Financials
Financial year 2025
Drug-Opera from Brussel, company number BE0408361981, closed financial year 2025 with a result of € 171,272 after tax. For that financial year Drug-Opera recorded a gross margin of € 2.6 million and equity of € 86,830. Compared with financial year 2024, the result moved from € 136,921 to € 171,272. Profitable, and profit is growing. The buffer shrank hard: equity is 67 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 15, 2026.
€ 86,830
▼ 67% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 171,272
▲ 25% vs 2024
Profit after tax over the fiscal year.
€ 51,904
▼ 59% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 350,000 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
€ 2.1 million
▲ 5% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 52,538
▼ 43% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 11,615
▼ 45% vs 2024
Loans from banks and other lenders, long and short.
€ 40,621
▼ 49% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 244,223
▼ 9% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 2,393,339 | € 2,986,476 | € 2,465,703 | € 2,613,998 | ▲ 6% |
| Profit after taxes | € 347,090 | € 448,032 | € 136,921 | € 171,272 | ▲ 25% |
| Equity | € 180,605 | € 328,637 | € 265,558 | € 86,830 | ▼ 67% |
| Total debts | € 801,921 | € 806,188 | € 570,691 | € 792,689 | ▲ 39% |
| Cash | € 251,918 | € 349,860 | € 127,762 | € 51,904 | ▼ 59% |
| Retained profit | € 118,605 | € 266,637 | € 203,558 | € 24,830 | ▼ 88% |
| Dividend | € 371,450 | € 300,000 | € 200,000 | € 350,000 | ▲ 75% |
| Bank debt | € 169,135 | € 30,415 | € 21,187 | € 11,615 | ▼ 45% |
| Balance sheet total | € 982,526 | € 1,134,825 | € 836,249 | € 879,519 | ▲ 5% |
Key figures of Drug-Opera, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Drug-Opera?
What happened at Drug-Opera in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 171,272 (▲ 25% vs 2024). Source: NBB ↗
- New establishment in Brussel. KBO
- Start of the company according to the CBE. KBO
In short
From € 347,090 profit in 2022 to € 171,272 profit in 2025.
Paid € 460,773 in corporate taxes since 2022.
Best year ever: 2023, with € 448,032 profit.
Paid out € 1.2 million in dividends to the owners in total.
A new publication or filing at Drug-Opera? We notify you, reason included.
Follow Drug-OperaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Drug-Opera are THOMAS MOEREMANS, JULIEN MOEREMANS, PIERRE MOEREMANS and DOMINIQUE MOERMANS.
Directors
According to the 2025 annual accounts
THOMAS MOEREMANS
Managing director
JULIEN MOEREMANS
Managing director
PIERRE MOEREMANS
Managing director
DOMINIQUE MOERMANS
Managing director
Establishments
Establishment units
Physical locations of this company
Grétrystraat 51
1000 Brussel
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
OVH Mail
Hosting
CLOUDFLARENET - Cloudflare, Inc., US
DNS
Cloudflare DNS
Website info
Features
Security
Network
Details
- Company number
- 0408.361.981
- VAT number
- BE 0408.361.981
- Registered office
- Grétrystraat 51, 1000 Brussel
- Names & denominations
- Drug-Opera
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 28 May 1971
- Peppol
- Active · Active since 6 Jan 2026
- Contact
- drugopera.be
- Activities · NACE
Restaurants van het traditionele type
Activiteiten van eetgelegenheden met volledige bediening
Cafés en bars
Cafés
Eetgelegenheden met volledige bediening
Activiteiten van eetgelegenheden met beperkte bediening, muv mobiele eetgelegenheden
Fastfoodzaken, snackbars, frituren en dergelijke
Eetgelegenheden met beperkte bediening